Mokuno H, Brady S, Kotite L, Herz J, Havel R J
Cardiovascular Research Institute, University of California, San Francisco 94143-0130.
J Biol Chem. 1994 May 6;269(18):13238-43.
The low density lipoprotein (LDL) receptor-related protein, which serves as the cell surface receptor for several proteins including alpha 2-macroglobulin-protease complexes, has been proposed to be a candidate hepatocytic receptor for chylomicron remnants through its recognition of apolipoprotein E. We have studied the effect of two ligands for this receptor, activated alpha 2-macroglobulin and the recently described 39-kDa protein that copurifies with the LDL receptor-related protein (receptor-associated protein), on the uptake and endocytosis of chylomicrons in intact rats and in isolated, perfused rat livers. Both of these ligands were rapidly taken up and endocytosed into the liver of rats. Chylomicrons from normal rats were injected in vivo and chylomicrons from estradiol-treated rats that were enriched in apolipoprotein E were added to liver perfusates. Prior administration of amounts of activated alpha 2-macroglobulin that saturated hepatic uptake mechanisms did not inhibit hepatic uptake or endocytosis of endogenously labeled cholesteryl esters of chylomicron particles in vivo or in perfused livers over a period of 15 min. By contrast, prior administration of saturating amounts of the receptor-associated protein (expressed in bacteria as a fusion protein with glutathione S-transferase) reduced hepatic uptake by about 30% and virtually abolished endocytosis. The receptor-associated protein inhibited hepatic uptake of human LDL in vivo by 70% and endocytosis by 81%. Our results show that receptor-associated protein-sensitive processes predominate in the overall pathways by which chylomicron remnants are endocytosed by rat liver. Furthermore, they show that the receptor-associated protein binds to and inhibits the function of the LDL receptor as well as the LDL receptor-related protein.
低密度脂蛋白(LDL)受体相关蛋白可作为包括α2-巨球蛋白-蛋白酶复合物在内的多种蛋白质的细胞表面受体,有人提出它可能是乳糜微粒残粒的肝细胞受体,因为它能识别载脂蛋白E。我们研究了该受体的两种配体——活化的α2-巨球蛋白和最近发现的与LDL受体相关蛋白(受体相关蛋白)共纯化的39 kDa蛋白,对完整大鼠及离体灌注大鼠肝脏中乳糜微粒摄取和内吞作用的影响。这两种配体都能迅速被大鼠肝脏摄取并内吞。给正常大鼠体内注射来自正常大鼠的乳糜微粒,并将富含载脂蛋白E的经雌二醇处理大鼠的乳糜微粒添加到肝脏灌注液中。预先给予能饱和肝脏摄取机制的活化α2-巨球蛋白,在15分钟内,并未抑制体内或灌注肝脏中乳糜微粒颗粒内源性标记胆固醇酯的肝脏摄取或内吞作用。相比之下,预先给予饱和量的受体相关蛋白(在细菌中表达为与谷胱甘肽S-转移酶的融合蛋白)可使肝脏摄取减少约30%,并几乎完全消除内吞作用。受体相关蛋白在体内可使人类LDL的肝脏摄取减少70%,内吞作用减少81%。我们的结果表明,受体相关蛋白敏感的过程在大鼠肝脏对乳糜微粒残粒进行内吞的总体途径中占主导地位。此外,结果还表明,受体相关蛋白能结合并抑制LDL受体以及LDL受体相关蛋白的功能。